Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

STAR50 Jun 2026 Index Rebalance: Post-Announcement Positioning

STAR50 Index Rebalance (Quantitative Event Study): Historical Patterns & Current Event Analysis

STAR50 Index Earning Revision (Feb): CAMBRICON, TRINA SOLAR, TRANSSION, Advanced Micro

STAR50 Index Earning Revision (Jan): TRINA SOLAR, JINKO SOLAR, BIWIN STORAGE, Ninebot

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

Yuanjie Semiconductor Technology / Index Rebalance

Yuanjie Semiconductor Technology (688498 CH)

<ul>
<li>We screen the STAR Market eligible universe ahead of the STAR50 May 2026 review.</li>
<li>Two names are high-conviction ADDs this cycle. A third sits at the entry boundary on lower confidence.</li>
<li>The DELETE slate has one clear case and two borderline names, with committee discretion the key variable.</li>
</ul>


We screen the STAR Market eligible universe ahead of the STAR50 May 2026 review.
Two names are high-conviction ADDs this cycle. A third sits at the entry boundary on lower confidence.
The DELETE slate has one clear case and two borderline names, with committee discretion the key variable.


Xiamen Amoytop Biotech Co Ltd (688278 CH)

Yuanjie Semiconductor Technology

STAR50 May 2026 Index Review Forecast